Vertex Pharmaceuticals Enterprise Value Trend

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

This module enables investors to look at Vertex Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 291.1 M, Cost of Revenue of 125.5 M or Gross Profit of 1.2 B, but also many exotic indicators such as Interest Coverage of 11.8293, Long Term Debt to Equity of 0.354 or PPandE Turnover of 4.1348. This module is a perfect complement to use when analyzing Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at analysis of Vertex Pharmaceuticals Correlation with competitors.

Vertex Pharmaceuticals Enterprise Value Marginal Breakdown

Showing smoothed Enterprise Value of Vertex Pharmaceuticals Incorpor with missing and latest data points interpolated. Enterprise Value (or EV) is usually referred to as Vertex Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Vertex Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Vertex Pharmaceuticals value than its market capitalization because it takes into account all of Vertex Pharmaceuticals Incorpor existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as [MarketCap] plus [DebtUSD] minus [CashnEqUSD].

49.08 B

          10 Years Trend
Slightly volatile
 Enterprise Value 

Vertex Pharmaceuticals Regression Statistics

Arithmetic Mean 18,534,949,414
Geometric Mean 13,846,445,700
Coefficient Of Variation 72.90
Mean Deviation 9,644,396,684
Median 17,180,147,515
Standard Deviation 13,512,757,563
Range 47,100,208,649
R Value 0.76
R Squared 0.57
Significance 0.00691
Slope 3,086,862,582

Vertex Pharmaceuticals Enterprise Value Over Time

2016  18,292,735,767 
2018  16,463,462,190 
2019  49,080,000,000 

Other Fundumenentals of Vertex Pharmaceuticals